Pretreatment MR imaging features of triple-negative breast cancer: Association with response to neoadjuvant chemotherapy and recurrence-free survival

Radiology

Volumn 281, Issue 2, 2016, Pages 392-400

  Bae, Min Sun ^a   Shin, Sung Ui ^a   Ryu, Han Suk ^a   Han, Wonshik ^a   Im, Seock Ah ^a   Park, In Ae ^a   Noh, Dong Young ^a   Moon, Woo Kyung ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; CONTRAST MEDIUM; GADOBENIC ACID; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; AGE; AGED; BREAST BIOPSY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; EDEMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATHOLOGIC COMPLETE RESPONSE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR RECURRENCE;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; CONTRAST MEDIA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84992159378     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2016152331     Document Type: Review

References (34)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triplenegative breast cancer. N Engl J Med 2010; 363(20):1938-1948.
2. Newman LA, Reis-Filho JS, Morrow M, Carey LA, King TA. The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. Ann Surg Oncol 2015;22(3):874-882.
3. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30(15): 1796-1804.
4. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26(8):1275-1281.
5. Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30(26):3242-3249.
6. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121(7):2750-2767.
7. Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2015;21(7): 1688-1698.
8. Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013;19(19): 5533-5540.
9. Bae MS, Park SY, Song SE, et al. Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression. Eur Radiol 2015;25(2):419-427.
10. Hylton NM, Blume JD, Bernreuter WK, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/ISPY TRIAL. Radiology 2012;263(3):663-672.
11. Prevos R, Smidt ML, Tjan-Heijnen VC, et al. Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review. Eur Radiol 2012;22(12):2607-2616.
12. Marinovich ML, Houssami N, Macaskill P, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst 2013; 105(5):321-333.
13. Costantini M, Belli P, Distefano D, et al. Magnetic resonance imaging features in triplenegative breast cancer: comparison with luminal and HER2-overexpressing tumors. Clin Breast Cancer 2012;12(5):331-339.
14. Baltzer PA, Yang F, Dietzel M, et al. Sensitivity and specificity of unilateral edema on T2w-TSE sequences in MR-Mammography considering 974 histologically verified lesions. Breast J 2010;16(3):233-239.
15. Marino MA, Clauser P, Woitek R, et al. A simple scoring system for breast MRI interpretation: does it compensate for reader experience? Eur Radiol 2015 Oct 19. [Epub ahead of print]
16. Uematsu T. Focal breast edema associated with malignancy on T2-weighted images of breast MRI: peritumoral edema, prepectoral edema, and subcutaneous edema. Breast Cancer 2015;22(1):66-70.
17. Kaiser CG, Herold M, Baltzer PA, et al. Is "prepectoral edema" a morphologic sign for malignant breast tumors? Acad Radiol 2015;22(6): 684-689.
18. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 2009; 250(3):638-647.
19. Kawashima H, Inokuchi M, Furukawa H, Kitamura S. Triple-negative breast cancer: are the imaging findings different between responders and nonresponders to neoadjuvant chemotherapy? Acad Radiol 2011;18(8):963-969.
20. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28(16): 2784-2795.
21. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25(1):118-145.
22. Morris EA, Comstock CE, Lee CH, et al. ACR BI-RADS magnetic resonance imaging. In: ACR BI-RADS Atlas, breast imaging reporting and data system. Reston, Va: American College of Radiology, 2013.
23. Rao A, Net J, Brandt K, et al. Identification of associations between radiologist-annotated imaging features and genomic alterations in breast invasive carcinoma, a TCGA Phenotype Research Group Study. American Association of Physicists in Medicine 57th Annual Meeting and Exhibition. Anaheim, Calif: American Association of Physicists in Medicine, 2015.
24. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-174.
25. Schmitz AM, Loo CE, Wesseling J, Pijnappel RM, Gilhuijs KG. Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype. Breast Cancer Res Treat 2014; 148(3):541-551.
26. Xu J, Wu X, Zhou WH, et al. Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer. PLoS One 2013; 8(2):e56919.
27. Schoenegger K, Oberndorfer S, Wuschitz B, et al. Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? Eur J Neurol 2009;16(7): 874-878.
28. Dietzel M, Zoubi R, Vag T, et al. Association between survival in patients with primary invasive breast cancer and computer aided MRI. J Magn Reson Imaging 2013;37(1):146-155.
29. Pickles MD, Lowry M, Manton DJ, Turnbull LW. Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators. Eur Radiol 2015;25(4): 1097-1106.
30. Mukhtar RA, Yau C, Rosen M, et al. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol 2013;20(12):3823-3830.
31. Sung JS, Jochelson MS, Brennan S, et al. MR imaging features of triple-negative breast cancers. Breast J 2013;19(6):643-649.
32. Park SH, Moon WK, Cho N, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010;257(1):56-63.
33. Humphries PD, Sebire NJ, Siegel MJ, Olsen ØE. Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 2007;245(3):848-854.
34. Grimm LJ, Anderson AL, Baker JA, et al. Interobserver variability between breast imagers using the fifth edition of the BI-RADS MRI lexicon. AJR Am J Roentgenol 2015;204(5): 1120-1124.